Goldfinch Bio to Participate in Upcoming Industry Conferences
CAMBRIDGE, Mass. – February 23, 2022 – Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced its participation in the following upcoming scientific and investor conferences:
The 4th Chronic Kidney Disease Drug Development Summit, March 1-3, 2022 (Hyatt Regency, Boston, MA)
- Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio, will give a presentation titled, “Leveraging a Precision Medicine Approach to Inform Future Directions of Drug Development in CKD.” The presentation will take place at 11:30 a.m. ET on Wednesday, March 2nd. Dr. Johnson will also participate in a panel discussion, “Challenges & Opportunities in Drug Development for Rare Kidney Diseases” at 4:00 p.m. ET on Wednesday, March 2nd.
- Candace Middlebrooks, Ph.D., Lead Statistical Geneticist of Goldfinch Bio, will present on “Integrating Genomic & Clinical Data to Increase the Probability of Successful Drug Discovery & Development for CKD Therapeutics.” The presentation will be held at 2:30 p.m. ET on Wednesday, March 2nd.
Cowen 42nd Annual Health Care Conference, March 7-9, 2022 (Virtual)
- Members of Goldfinch Bio’s management team will participate in one-on-one meetings.
About Goldfinch Bio
Goldfinch Bio, Inc. is a clinical stage biotechnology company focused on delivering disease-modifying precision medicines that bring hope and renewed quality of life to people living with kidney diseases. We aspire to save kidneys and end dialysis. Our precision medicine product engine allows us to discover, validate and drug novel targets that may allow us to better treat subsets of patients, within a heterogeneous kidney disease, based on common characteristics. We have a robust pipeline of novel, precision medicine product candidates targeting kidney diseases with significant unmet need, including two clinical-stage assets. Visit us at www.goldfinchbio.com to learn more.